# ‚öîÔ∏è CLINICAL TRIAL DOSSIER

**NCT ID**: NCT01247779  
**Trial Title**: Perioperative Morbidity in Gyneco-oncology According to the Procedure : Coelioscopy Versus Robot-assisted Coelioscopy  
**Patient ID**: ayesha_001  
**Generated**: 2025-11-14T19:56:29.502951  
**Generated By**: JR2 (Dossier Sidekick)

---

## 1. TRIAL OVERVIEW

**Title**: Perioperative Morbidity in Gyneco-oncology According to the Procedure : Coelioscopy Versus Robot-assisted Coelioscopy  
**Phase**:   
**Status**: COMPLETED  
**Sponsor**:   
**Estimated Enrollment**: 0  
**Primary Endpoint**: None

**ClinicalTrials.gov**: https://clinicaltrials.gov/study/NCT01247779

---

## 2. ELIGIBILITY ASSESSMENT

**Summary**: 4/6 criteria met

### Eligibility Criteria Table

| Criterion | Status | Confidence | Notes |
|-----------|--------|------------|-------|
| Disease Match | ‚úÖ PASS | 0.90 | Ovarian/gynecologic match: ["cervical cancer", "uterus cancer", "ovarian cancer"] |
| Treatment Line | ‚úÖ PASS | 0.80 | Line match assumed (not explicitly excluded) |
| Biomarker Requirements | ‚úÖ PASS | 1.00 | No biomarker requirements |
| Location (NYC Metro) | ‚úÖ PASS | 0.50 | No location data (assume match) |
| Inclusion Criteria (Full Text Available) | üìã REVIEW | 0.80 | See full text: * patient with uterus cancer depending on hysterectomy ¬± pelvic lymphadenectomy or a restadification
* patient with cervical cancer depending on enlarged colpo-hysterectomy ¬± pelvic lymphadenectomy or... |
| Exclusion Criteria (Full Text Available) | üìã REVIEW | 0.80 | See full text: * metastatic disease
* pregnant or breastfeeding woman
* patient unable to proceed follow-up visit, because of geographic, social or mental reasons... |

---

## 3. STRATEGIC SCENARIOS

### Best Case

**Eligibility Probability**: 66.7%

**Scenario**: All pending biomarker tests return favorable results

**Eligibility Level**: HIGH

### Most Likely

**Eligibility Probability**: 66.7%

**Scenario**: 50% of pending tests pass, some may require additional screening

**Eligibility Level**: MODERATE

### Challenge

**Eligibility Probability**: 66.7%

**Scenario**: Some pending tests fail, may need alternative trials

**Eligibility Level**: LOW

---

## 4. TACTICAL RECOMMENDATIONS

| Action | Lab | Cost | Timeline | Priority | Rationale |
|--------|-----|------|----------|----------|----------|
| Proceed with trial enrollment | N/A | N/A | Immediate | HIGH | All eligibility criteria met |

---

## 5. DRUG MECHANISMS

### gynecologic

**Mechanism (Technical)**: [NEEDS VERIFICATION] Mechanism not found in database for gynecologic

**Mechanism (Layman)**: [NEEDS VERIFICATION] Please consult oncologist for mechanism explanation.

**Evidence Tier**: UNKNOWN

---

## 6. LOCATION DETAILS

No location data available.

---

## 7. TIMELINE

**Study Start Date**: 

**Primary Completion Date**: 

---

## 8. FULL ELIGIBILITY TEXT

### Inclusion Criteria

* patient with uterus cancer depending on hysterectomy ¬± pelvic lymphadenectomy or a restadification
* patient with cervical cancer depending on enlarged colpo-hysterectomy ¬± pelvic lymphadenectomy or a surgery after concomitant radiochemotherapy, or lombo aortic lymphadenectomy for a locally advanced cancer, or a restadification
* patient with cervical cancer depending on a restadification
* patient aged over 18 years
* previous antitumor treatment allowed but necessarily disrupted 20 days before inclusion
* WHO score equal or inferior to 3
* cirrhosis-related Child-Pugh score under or equal to A7 are allowed
* life expectancy equal or superior to 12 weeks
* patient affiliated to health insurance
* dated and signed informed consent

### Exclusion Criteria

* metastatic disease
* pregnant or breastfeeding woman
* patient unable to proceed follow-up visit, because of geographic, social or mental reasons

---

## 9. CONTACT INFORMATION

Contact information not available.

---

## 10. PROVENANCE

**Generated By**: JR2

**Data Sources**: SQLite, Diffbot, DRUG_MECHANISM_DB

**Confidence Flags**: [INFERRED], [NEEDS VERIFICATION]

---

**RESEARCH USE ONLY (RUO)** - This dossier is for research purposes only and should not be used for clinical decision-making without proper medical review.

